Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109238 · ClinicalTrials.gov registry record
A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma
A clinical trial, sponsored by Giselle Sholler.
- Completed
- Registry status
- 5
- Enrollment target
NCT01109238: Completed study, sponsored by Giselle Sholler.
NCT01109238 is a clinical trial that has completed, run by Giselle Sholler. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01109238 has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The investigators are studying new ways to make treatment decisions for these types of cancer. Technologies at the Van Andel Research Institute (VARI) are available to determine a tumor's molecular makeup (gene expression profile). This technology (called "Xenobase") is being used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer. The researchers at VARI have filed a patent on the Xenobase and the specific network analysis method that the investigators will be using as part of this study. A specimen obtained from the tumor during a recent surgical, biopsy, or bone marrow procedure will be sent to the Van Andel Research Institute. Researchers will attempt to identify the molecular makeup within the specimen, as well as in blood and urine samples in patients with aggressive and/or refractory cancer. This additional testing is different than the routine tests currently performed at the hospital for the evaluation of cancer. The goals of this part of the study are: To determine if the investigators tumor board committee (at minimum a panel of 3 oncologists and 1 pharmacist) can use patient specific cancer cells to make real-time treatment decision using patient specific genetic information, and predicted therapies generated in the Xenobase report.
Primary Outcome
To pilot 5 patients to evaluate the feasibility of using predictive modeling based on genome-wide mRNA expression profiles of bone marrow derived neuroblastoma cells or tumor biopsies to make real-time treatment decisions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-07 |
What the finished NCT01109238 record still lists
NCT01109238 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01109238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01109238 about?
NCT01109238 is a clinical study titled "A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma". The investigators are studying new ways to make treatment decisions for these types of cancer. Technologies at the Van Andel Research Institute (VARI) are available to determine a tumor's molecular makeup (gene expression profile). This technology (called "Xenobase") is being used to discover new wa...
What is the current status of trial NCT01109238?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2010-04. Estimated completion is 2010-07.
Who is sponsoring clinical trial NCT01109238?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia